Mostafa Ibrahim

Mostafa Ibrahim

Auto-generated profile, based on publicly available information

Mostafa Ibrahim

Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2018 in Gut
Verified
Journal Article
Open access
PDF file
MIMostafa Ibrahim
Mostafa Ibrahim
AEAhmed El-Mikkawy
Ahmed El-Mikkawy
MHMohamed Abdel Hamid
Mohamed Abdel Hamid
HAHaitham Abdalla
Haitham Abdalla
ALArnaud Lemmers
Arnaud Lemmers
JDJacques Devière
Jacques Devière
Background Acute variceal bleeding (AVB) requires early therapeutic management by experienced endoscopists that often poses logistical challenges for hospitals. We assessed a different management concept with early application of haemostatic powder—which does not require high endoscopic expertise—added to conventional management in a randomised trial. Methods Cirrhotic patients with AVB received standard medical therapy and were randomised to either immediate endoscopy with haemostatic powder application within 2 hours of admission, followed by early elective endoscopy on the next day, that is, within 12–24 hours of admission for definitive treatment (study group) or to early elective endoscopy only (control group). In both groups, failures to achieve clinical haemostasis until the time of early elective endoscopy underwent rescue endoscopy with attempted conventional haemostasis. Primary outcome was endoscopic haemostasis at the elective endoscopy. Results Of 86 randomised patients with AVB, 5/43 in the study group required rescue endoscopy for failure of controlling spurting bleeding (n=4) after powder application or for early bleeding recurrence in one patient who died before repeating rescue endoscopy. In the control group, 13/43 patients required rescue endoscopic haemostasis for failure of clinical haemostasis (12%vs30%, p=0.034). In the remaining patients, early elective endoscopic haemostasis was achieved in all 38 patients in the study group, while all remaining 30 patients in the control group had fresh gastric blood or (10%) spurting bleeding at early elective endoscopy with successful haemostasis in all of them. Six-week survival was significantly improved in the study group (7%vs30%, p=0.006). Conclusion The new concept of immediate powder application improves early clinical and endoscopic haemostasis. This simplified endoscopic approach may have an impact on early and 6-week survival. Trial registration number NCT03061604.

20 March 2013 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
FMFrancois MION
Francois MION
MIMostafa Ibrahim
Mostafa Ibrahim
SMSophie Marjoux
Sophie Marjoux
TPThierry Ponchon
Thierry Ponchon
SDSonia Dugardeyn
Sonia Dugardeyn
JDJacques Deviere
Jacques Deviere

1 May 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
MIMostafa Ibrahim
Mostafa Ibrahim
IMIbrahim Mostafa
Ibrahim Mostafa
JDJacques Devière
Jacques Devière

1 November 2013 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
MIMostafa Ibrahim
Mostafa Ibrahim
AEAhmed El-Mikkawy
Ahmed El-Mikkawy
IMIbrahim Mostafa
Ibrahim Mostafa
JDJacques Devière
Jacques Devière

1 June 2015 in United European Gastroenterology Journal
Verified
Journal Article
Open access
MIMostafa Ibrahim
Mostafa Ibrahim
AEAhmed El-Mikkawy
Ahmed El-Mikkawy
HAHaitham Abdalla
Haitham Abdalla
IMIbrahim Mostafa
Ibrahim Mostafa
JDJacques Devière
Jacques Devière
Background and objectives: This study aimed to test the safety and efficacy of Hemospray® for emergency control of acute variceal bleeding (AVB) due to portal hypertension in cirrhotic patients.Patients and methods: This single‐arm, prospective trial, conducted at two hospitals in Belgium and Egypt, included patients admitted to the emergency room with hematemesis and/or melena and known or suspected liver cirrhosis. All patients received urgent hemodynamic stabilization, octreotide (50 mcg bolus then 25 mcg/hour for 24 hours) and intravenous ceftriaxone (1 g/hour). Endoscopy to confirm AVB and Hemospray® application (if indicated) was performed within six hours of admission. Patients were kept under observation for 24 hours and underwent second endoscopy and definitive therapy (band ligation and/or cyanoacrylate injection in cases of gastric varices) the next day.Results: Thirty‐eight patients were admitted for suspected AVB, and 30 of these had confirmed AVB (70% male; mean age 59.5 years (range, 32.0–73 years)). Child‐Pugh class C liver disease was present in 53.4%. Esophageal varices were observed in 83.4% of patients, gastric varices in 10%, and duodenal varices in 6.6%. Spurting bleeding at the time of endoscopy was observed in 43.4%. One patient developed hematemesis six hours after Hemospray® application and underwent emergency endoscopic band ligation. No major adverse events or mortalities were observed during 15‐day follow‐up.Conclusion: Hemospray® application was safe and effective at short‐term follow‐up for emergency treatment of AVB in cirrhotic patients.

4 May 2023 in JHEP Reports
Verified
Journal Article
Open access
Zhaohui BaiZhaohui Bai
Zhaohui Bai
NMNahum Méndez-Sánchez
Nahum Méndez-Sánchez
FRFernando Romeiro
Fernando Romeiro
AMAndrea Mancuso
Andrea Mancuso
CPCyriac Abby Philips
Cyriac Abby Philips
XQXingshun Qi
Xingshun Qi
Numerous studies have evaluated the role of human albumin (HA) in managing various liver cirrhosis-related complications. However, their conclusions remain partially controversial, probably because HA was evaluated in different settings, including indications, patient characteristics, and dosage and duration of therapy. Thirty-three investigators from 19 countries with expertise in the management of liver cirrhosis-related complications were invited to organise an International Special Interest Group. A three-round Delphi consensus process was conducted to complete the international position statement on the use of HA for treatment of liver cirrhosis-related complications. Twelve clinically significant position statements were proposed. Short-term infusion of HA should be recommended for the management of hepatorenal syndrome, large volume paracentesis, and spontaneous bacterial peritonitis in liver cirrhosis. Its effects on the prevention or treatment of other liver cirrhosis-related complications should be further elucidated. Long-term HA administration can be considered in specific settings. Pulmonary oedema should be closely monitored as a potential adverse effect in cirrhotic patients receiving HA infusion. Based on the currently available evidence, the international position statement suggests the potential benefits of HA for the management of multiple liver cirrhosis-related complications and summarises its safety profile. However, its optimal timing and infusion strategy remain to be further elucidated. Thirty-three investigators from 19 countries proposed 12 position statements on the use of human albumin (HA) infusion in liver cirrhosis-related complications. Based on current evidence, short-term HA infusion should be recommended for the management of HRS, LVP, and SBP; whereas, long-term HA administration can be considered in the setting where budget and logistical issues can be resolved. However, pulmonary oedema should be closely monitored in cirrhotic patients who receive HA infusion.